Natera, Inc. (45E.F)
| Previous Close | 86.00 |
| Open | 84.00 |
| Bid | 0.00 x 29600 |
| Ask | 0.00 x 28500 |
| Day's Range | 84.00 - 86.50 |
| 52 Week Range | 49.00 - 103.00 |
| Volume | |
| Avg. Volume | 6 |
| Market Cap | 8.085B |
| Beta (5Y Monthly) | 1.39 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.60 |
| Earnings Date | May 09, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 150.11 |
Business WireNatera to Report its First Quarter 2024 Results on May 9
AUSTIN, Texas, May 01, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its first quarter ended March 31, 2024, after the market close on May 9, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).
Business WireNatera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage
AUSTIN, Texas, May 01, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of a new cfDNA-based fetal RhD test. This comes at a critical time for the healthcare industry, helping physicians navigate patient care given nationwide shortages of Rho(D) immune globulin therapy (RhIg).
Business WireNatera Announces Significant Milestone with 200+ Peer-Reviewed Publications
AUSTIN, Texas, April 22, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that it has passed a significant milestone with the publication of more than 200 peer-reviewed papers highlighting Natera’s technology in the scientific literature.
